BioBS, these dozens of collaborations may be key to Peregrine’s path forward.
I’m viewing the collaborations as demonstrations of the enhanced efficacies that can be realized through multiple combinations of upstream anti-PS and downstream anti-XYZ immuno mAbs. We know that anti-PS initiates the natural immune cascade right from the diseased cell wall where the exposed PS is located. We have seen that this process creates an immune environment that is conducive to increased success for an associated downstream immuno mAb.
The combining of two downstream immuno mAbs, which focus only on the T-cell has its limitations and possible dangers for patients.
These many Peregrine demonstration trials may have the collaborating entities supplying their downstream immuno mAbs so that they can be combined with PPHM’s upstream anti-PS mAbs. Investors have seen the quality of these combinations in two types of downstream immunotherapy mAbs, anti-CTLA-4, and anti-PD-1, in Peregrine publications. These demonstrations leave no question about the substantial increase in efficacy that is available in the upstream/downstream combinations.
At this point, we can only guess which companies are involved with the collaborations/demonstrations.
The Bavi plus Yervoy advanced melanoma trial has my full attention. Has BMY supplied the Yervoy to Peregrine, or UTSW, for this trial?
There could be a number of partnerships that might come from these combination demonstrations, but I don’t see this as a clear path forward for multiple partnering in this downstream immuno market. There are a growing number of companies with very similar downstream immunotherapy mAbs. If I’m a BP with an anti-PD-1 mAb, and I make a partnership with PPHM to govern combinations with anti-PS, I certainly don’t want PPHM making the same deal with another anti-PD-1 marketer. I lose my advantage. A BP would need to dominate that particular combination market niche with anti-PS, rather than share it with five or ten other anti-PD-1 marketers.
I am less inclined to think that partnerships will work well for PPMH, or partners, unless there is exclusivity. So which of these anti-PD-1 companies are going to see the these upstream/downstream combination data and fold? Which will hold?
I believe the advantage will be with a company that has, at least, one other downstream immuno mAb, like anti-CTLA-4, or anti-PDL-1.
Finally what I expect will happen is that a major BP, at some trigger point, will move to an acquisition of Peregrine, that involves an unrefusable offer.
What that would be, and when, who knows?
IMO
sunstar
